Efficacy and Safety of Direct Oral Factor Xa
Inhibitors Compared With Those of Warfarin in
Patients With Morbid Obesity: A Single-Center,
Retrospective Analysis of Chart Data

Kushnir M, Choi Y, Eisenberg R, Rao D, Tolu S, Gao J, Mowrey W, and Billett HH.
Objective: To investigate the efficacy and safety of the DOACs,
apixaban and rivaroxaban, in comparison with those of warfarin
in morbidly obese patients